Pan American Health Organization · 1st edition, 2021
Evidence-based recommendations on drug choice and dosing for mass treatment of taeniasis in endemic areas to control neurocysticercosis.
- Issuer
- Pan American Health Organization
- Edition
- 1st edition, 2021
- Audience
- Policymakers, technical and programme staff at governmental institutions and organisations involved in planning, implementing, monitoring and evaluating preventive chemotherapy programmes for T. solium control.
- Evidence
- GRADE methodology; very low certainty evidence for all recommendations; systematic review of randomized controlled trials, controlled before-after studies, and observational studies; expert consensus via Guideline Development Group.
- Reviewed
- 19 Oct 2026 · GMJ
What this guideline says
GMJ summary
This guideline provides the first evidence-based recommendations for preventive chemotherapy (PC) to control Taenia solium taeniasis in endemic populations. Taeniasis, caused by the adult tapeworm, is a key intervention point because human tapeworm carriers shed eggs that cause neurocysticercosis—the leading cause of acquired epilepsy in low-income countries. Neurocysticercosis accounted for an estimated 2.8 million disability-adjusted life years in 2015, disproportionately affecting poor communities where pigs roam free and sanitation is inadequate.
The guideline offers three drug options for PC programmes: niclosamide 2 g (dose-adjusted for children), praziquantel 10 mg/kg, and albendazole 400 mg daily for three consecutive days. All recommendations are conditional due to very low certainty evidence. Niclosamide is poorly absorbed and carries minimal neurological risk. Praziquantel and albendazole can cross the blood-brain barrier and potentially trigger latent neurocysticercosis, requiring active surveillance for neurological adverse events for at least three days post-treatment. Albendazole triple-dose is recommended only when no alternative exists. The guideline also addresses operational synergies: in school-age children co-endemic for both T. solium and soil-transmitted helminths, praziquantel for taeniasis (10 mg/kg) can be given simultaneously with albendazole for STH (400 mg single dose).
Implementation requires community-wide treatment (not only school-age children), active adverse-event surveillance, trained health workers, and integration with One Health approaches targeting pig vaccination, sanitation, and health education. PC alone is insufficient; sustained control demands multisectoral action across human, animal, and environmental health.
Key points
For clinicians — doses and thresholds as stated in the guideline
- Niclosamide 2 g single dose (1 g for children 10–35 kg; 0.5 g for <10 kg) is suggested for PC in endemic populations; poorly absorbed, minimal neurological risk.
- Praziquantel 10 mg/kg is suggested for PC, with mandatory active surveillance and medical referral for neurological adverse events for ≥3 days post-treatment.
- Albendazole 400 mg per day for three consecutive days may be considered only if no alternative available, with mandatory active surveillance for neurological events.
- PC should target the entire community, not only school-age children; exclude children <30 kg from albendazole triple-dose, and all pregnant women in first trimester from any drug.
- People with symptoms of neurocysticercosis (severe headache, seizures, epilepsy) or subcutaneous cysticercosis must be excluded from praziquantel or albendazole PC.
- Praziquantel and albendazole for taeniasis should be given fasting (≥2 hours since last meal, 30 min before next meal) and never with grapefruit juice to minimize absorption.
- In school-age children co-endemic for T. solium and STH, praziquantel 10 mg/kg (taeniasis) plus albendazole 400 mg single dose (STH) can be given simultaneously.
- Active adverse-event surveillance required for ≥3 days after last dose of praziquantel or albendazole, followed by passive surveillance for ≥7 additional days; train health workers in recognition and referral of neurological events.
Drug options for PC for taeniasis considering synergies with other co-endemic diseases
Table extracted from the guideline
| Target diseases | Drug options for preventive chemotherapy |
|---|---|
| Taeniasis only | Niclosamide (2 g) OR Praziquantel (10 mg/kg) OR Albendazole (400 mg per day for three consecutive days) |
| Taeniasis and: schistosomiasis, or clonorchiasis, or opisthorchiasis | Praziquantel (40 mg/kg as a higher dose is required for trematode parasites) |
| Taeniasis and soil-transmitted helminths | Niclosamide (2 g) plus albendazole (400 mg, single dose) administered on separate days OR Praziquantel (10 mg/kg) plus albendazole (400 mg, single dose) OR Albendazole (400 mg per day for three consecutive days) |
Source: Pan American Health Organization, Guideline for Preventive Chemotherapy for the Control of Taenia solium Taeniasis. Reproduced in summary form.
From the guideline
Verbatim
“Preventive chemotherapy using niclosamide at 2 g (dose adjusted for children) is suggested as a public health intervention for the control of Taenia solium taeniasis in endemic populations.”
Editor’s perspective
Why this matters for Georgia and the region
Prof. Giorgi Pkhakadze, MD, MPH, PhD
Editor-in-Chief, Georgian Medical Journal · Chair, Public Health Institute of Georgia · WHO consultant, health and migration
As WHO consultant on health and migration and chair of Georgia's Public Health Institute, I recognise that while T. solium is not a documented public-health problem in Georgia today, this guideline is highly relevant for countries in our region with backyard pig-keeping and sanitation gaps, and for Georgian clinicians encountering imported neurocysticercosis in migrant and refugee populations. The most important implementation message is that preventive chemotherapy is only one tool: sustained control demands a One Health approach integrating veterinary pig vaccination, community sanitation, and health education—precisely the multisectoral coordination that Georgia's universal health coverage infrastructure can support. The critical caveat is that praziquantel and albendazole can precipitate seizures in people with undiagnosed neurocysticercosis, so any programme must establish active neurological surveillance, train primary-care teams in seizure recognition and referral, and involve national epilepsy services from the outset. Without that safety net, the risk of serious harm outweighs benefit, especially in settings with high disease prevalence.
ORCID 0000-0001-7609-4515 · Perspective written for the GMJ Guidelines Library, 19 Oct 2026
Applicability
Georgia and the South Caucasus
Georgia and neighbouring South Caucasus countries are not currently mapped as T. solium-endemic in WHO databases, but the parasite is present in parts of Eastern Europe, Central Asia, and the former Soviet Union where pig-keeping practices and sanitation infrastructure resemble those in endemic settings. National programmes should conduct epidemiological mapping using porcine cysticercosis surveillance and human epilepsy/neurocysticercosis case data to determine whether preventive chemotherapy is warranted. Where taeniasis is confirmed, health authorities can request niclosamide or praziquantel from WHO and must establish adverse-event surveillance systems, train primary-care providers in neurological-event recognition, and integrate PC with existing deworming programmes for soil-transmitted helminths. Given Georgia’s universal health coverage programme and well-developed primary health care network, operational feasibility is high, but success depends on One Health collaboration between human health, veterinary services, and environmental sanitation sectors.
Questions this guideline answers
Quick answers
Which drug should be chosen for preventive chemotherapy for taeniasis?
The choice depends on co-endemic diseases, drug availability, and capacity for adverse-event surveillance. Niclosamide 2 g is poorly absorbed and safest for neurological risk. Praziquantel 10 mg/kg is effective and allows synergy with schistosomiasis programmes (at 40 mg/kg), but requires active surveillance for neurological events. Albendazole 400 mg daily for three days is only recommended when no alternative exists, also requiring mandatory neurological surveillance. In areas co-endemic for soil-transmitted helminths, praziquantel plus single-dose albendazole 400 mg can be given simultaneously to school-age children.
Why must praziquantel and albendazole be given fasting and never with grapefruit juice?
Praziquantel and albendazole bioavailability increases significantly with food (especially high-fat or high-carbohydrate meals) and with grapefruit juice. For taeniasis, the goal is to act locally in the gut with minimal systemic absorption to reduce the risk of triggering latent neurocysticercosis. Ideally, administer at least two hours after the last meal and 30 minutes before the next meal. (For schistosomiasis, praziquantel 40 mg/kg is intentionally given with food to increase absorption.)
Who should be excluded from preventive chemotherapy for taeniasis?
Exclude: (1) pregnant women in the first trimester or suspected early pregnancy (all drugs); (2) children <30 kg if using albendazole triple-dose; (3) people with symptoms compatible with neurocysticercosis (severe/progressive headache, seizures of unknown cause, epilepsy) or subcutaneous cysticercosis if using praziquantel or albendazole. Note that symptom-based exclusion does not eliminate risk in asymptomatic neurocysticercosis carriers. Children <2 years are generally not included as tapeworm infection is unlikely.
What adverse-event surveillance is required after treatment?
For praziquantel or albendazole: active surveillance for at least three days after the last dose, followed by passive surveillance for at least seven additional days. Train community health workers and primary-care providers to recognise, report, and refer neurological events (seizures, severe headache). Involve the national epilepsy programme as a collaborative partner. For niclosamide, standard adverse-event monitoring suffices. Report coverage and adverse events disaggregated by age and sex, following WHO manuals on preventive chemotherapy monitoring.
Related on GMJ
Interconnected resources
Conditions A–Z
GMJ News coverage
Quality & accreditation
Other guidelines on this topic
- Guideline for the Treatment of Leishmaniasis in the Americas
- Guidelines for the Clinical Diagnosis and Treatment of Dengue, Chikungunya, and Zika
- Microplanning manual to guide implementation of preventive chemotherapy to control and eliminate neglected tropical diseases
- Infection Prevention and Control for the Management of Mpox in People in Situations of Vulnerability such as Prisons and Other Custodial Facilities
- Recommendations for Adapting Emergency Medical Teams (EMTs) at Temporary COVID-19 Vaccination Sites
- Issuer
- Pan American Health Organization
- Type
- Procedures, manuals, guidelines
- Edition
- 1st edition, 2021
- Status
- Current
- Published
- 2021-01-01
- Languages
- English; Spanish (forthcoming); French/Portuguese summaries (conditional)
- Scope
- Preventive chemotherapy (mass drug administration, targeted or selective chemotherapy) for T. solium taeniasis in endemic human populations; does not cover clinical treatment of neurocysticercosis.
- Audience
- Policymakers, technical and programme staff at governmental institutions and organisations involved in planning, implementing, monitoring and evaluating preventive chemotherapy programmes for T. solium control.
- Licence
- CC BY-NC-SA 3.0 IGO
- ISBN
- 978-92-75-12371-3 (print)
- Evidence
- GRADE methodology; very low certainty evidence for all recommendations; systematic review of randomized controlled trials, controlled before-after studies, and observational studies; expert consensus via Guideline Development Group.
- Next review
- Assumed valid until at least 2025 unless new significant evidence arises.
- Record history
- Created 19 Oct 2026 · updated 19 Oct 2026 · next check Apr 2027
Pan American Health Organization. Guideline for Preventive Chemotherapy for the Control of Taenia solium Taeniasis. Washington, D.C.: PAHO; 2021. Licence: CC BY-NC-SA 3.0 IGO. https://doi.org/10.37774/9789275123720GMJ Guidelines Library records are original summaries written by the GMJ editorial team from the issuer’s published document and reviewed by a physician. They do not replace the full guideline. The document is the copyright of its issuer and is linked, not hosted. Spotted an error or a newer edition? Tell the Guidelines Desk.
Was this article helpful?
